Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer

Annals of Oncology

Volumn 23, Issue 7, 2012, Pages 1766-1771

  Jenkins, P ^a   Scaife, J ^a   Freeman, S ^b  

^a CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Chemotherapy; Febrile neutropaenia; Risk models

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; HIGH RISK PATIENT; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SINGLE DRUG DOSE; VALIDATION STUDY;

EID: 84864319287     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr493     Document Type: Article

References (29)

1. Kuderer NM, Dale DC, Crawford J et al.. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106: 2258-2266.
2. Martin M, Lluch A, Segui MA et al.. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006; 17: 1205-1212.
3. Schutz FA, Jardim DL, Je Y, Choueiri TK. Haematologic toxicities associated with the addition of bevacizumab in cancer patients. Eur J Cancer 2011; 47: 1161-1174.
4. Jenkins P, Freeman S. Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Ann Oncol 2009; 20: 34-40.
5. Schwenkglenks M, Pettengell R, Jackisch C et al.. Risk factors for chemotherapyinduced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study. Support Care Cancer 2011; 19: 483-490.
6. Lyman GH, Kuderer NM, Crawford J et al.. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011; 117: 1917-1927.
7. Aapro MS, Bohlius J, Cameron DA et al.. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2010; 47: 8-32.
8. Martin M, Pienkowski T, Mackey J et al.. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2302-2313.
9. Jenkins P, Elyan S, Freeman S. Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer. Eur J Cancer 2007; 43: 544-548.
10. Jenkins P, Wallis R. Dose-rounding of adjuvant chemotherapy for breast cancer: an audit of toxicity. J Oncol Pharm Pract 2010; 16: 251-255.
11. Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 2010; 21: v248-v251.
12. Penack O, Buchheidt D, Christopeit M et al.. Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology. Ann Oncol 2011; 22: 1019-1029.
13. Rivera E, Haim Erder M, Fridman M et al.. First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study. Breast Cancer Res 2003; 5: R114-R120.
14. Silber JH, Fridman M, Dipaola RS et al.. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 1998; 16: 2392-2400.
15. Ray-Coquard I, Borg C, Bachelot T et al.. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 2003; 88: 181-186.
16. Alexandre J, Rey E, Girre V et al.. Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann Oncol 2007; 18: 168-172.
17. Moreau M, Klastersky J, Schwarzbold A et al.. A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol 2009; 20: 513-519.
18. Von Minckwitz G, Kummel S, Du Bois A et al.. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 2008; 19: 292-298.
19. Burris HA, Belani CP, Kaufman PA et al.. Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin's lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract 2010; 6: 133-140.
20. Crawford J, Ozer H, Stoller R et al.. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with smallcell lung cancer. N Engl J Med 1991; 325: 164-170.
21. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
22. Hughes WT, Armstrong D, Bodey GP et al.. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
23. Cullen M, Steven N, Billingham L et al.. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353: 988-998.
24. Bucaneve G, Micozzi A, Menichetti F et al.. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353: 977-987.
25. Timmer-Bonte JN, De Boo TM, Smit HJ et al.. Prevention of chemotherapyinduced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 2005; 23: 7974-7984.
26. Holmes FA, Jones SE, O'shaughnessy J et al.. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002; 13: 903-909.
27. Green MD, Koelbl H, Baselga J et al.. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
28. Borg C, Ray-Coquard I, Philip I et al.. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer 2004; 101: 2675-2680.
29. Cruciani M, Malena M, Bosco O et al.. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 2003; 21: 4127-4137.